August 28, 2023 AvantGen Forms Therapeutic Subsidiary Alanis Therapeutics Inc.

August 28, 2023 AvantGen Forms Therapeutic Subsidiary Alanis Therapeutics Inc. AvantGen, the San Diego Antibody Engineering Company, announced today the formation of Alanis Therapeutics Incorporated (ATI), a Delaware Corporation Registration Number 7643699. Dr. Xiaomin Fan, Ph.D., Founder and CEO of AvantGen will serve as the Chairman of ATI which will develop AvantGen’s antibody platform for various therapeutic applications. This includes the antagonist antibody to jagged-1, the ligand of notch1 signaling, which has been studied in collaboration with investigators at Columbia University as an oncogenic driver between osteoblasts and leukemic stem cells in MDS and AML. Dr. Fan said: “We’ve reached an important milestone in the Company’s evolution to have products with therapeutic potential to be developed by Alanis. We look forward to moving our lead asset into the clinic in collaboration with our investigators at Columbia University.”